On August 28, Boston Scientific fell 3.09% in regular trading, trading at $46.67/share, with turnover of $549 million.

The decline reflects continued pressure from two major adverse developments. The company disclosed a cybersecurity incident to the SEC that has disrupted global operations, affecting IT systems, order processing, and customer shipments. The timeline for full restoration remains unknown, and the company has not yet determined whether the incident will have a material impact.

Simultaneously, the FDA classified the company's recall of ENROUTE Transcarotid Neuroprotection System percutaneous catheters as Class I — the most serious level — due to the risk of arterial sheath tip separation that could lead to embolism and stroke. One serious injury has been reported.

These twin headwinds compound existing fundamental concerns, including Watchman device revenue expected to decline mid-to-high single digits year-over-year in the second half, and a full-year adjusted EPS guidance cut to $3.28–$3.32, below consensus of $3.36. Multiple analysts have lowered price targets, while Argus downgraded the stock to Hold.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)